poisar

Stocks · News reference

Viking Therapeutics Q2 EPS $(1.10) Beats $(1.25) Estimate

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

VKTX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Zacks.Com

    Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know

    Viking Therapeutics (VKTX) gained 1.43% in the latest session, outperforming the S&P 500's 1.06% gain. However, the stock has depreciated 0.03% over the past month, underperforming the Medical sector's 5.75% gain. The company is expected to report an EPS of -$1 (down 23.46% YoY) with full-year consensus estimates of -$4.47 EPS and $0 million revenue. VKTX holds a Zacks Rank #3 (Hold) rating, while its industry (Medical - Biomedical and Genetics) ranks in the bottom 34% of all industries.

    VKTX
  2. Prosper Junior Bakiny

    3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong

    While three Wall Street analysts have bullish $100 price targets on Viking Therapeutics (implying a tripling), the author argues this is overly optimistic. Viking's weight-loss drug VK2735 would need near-flawless phase 3 data showing 23-26% mean weight loss to justify such gains, and any clinical setback could sink the stock. The author recommends only risk-tolerant investors consider a small position.

    VKTX
  4. Lee Samaha

    Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?

    Viking Therapeutics has sufficient cash reserves ($502M) to fund operations through 2028, with a key near-term catalyst in Q3 2026 when phase 1 maintenance trial data for its lead drug VK2735 will be released. This data could significantly impact investor sentiment regarding the company's dual-formulation strategy (subcutaneous injection followed by oral maintenance), though it's unlikely to derail the ongoing phase 3 trials. The trial results will inform dosing decisions for upcoming extension studies.

    VKTX